This study is in progress, not accepting new patients
An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
Summary
- Eligibility
- for people ages 4 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Edward Hsiao
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Edward Hsiao
MD: MD, PhD, Johns Hopkins Medical School, 2001 Residency: Johns Hopkins Hospital, Baltimore, MD, Internal Medicine, 2001-2004 Fellowship: UCSF, Division of Diabetes, Endocrinology and Metabolism, 2004-2007 Board Certifications: Internal Medicine, 2004; Endocrinology and Metabolism, 2006 My research is driven by a desire to understand how major hormonal and regulatory pathways…
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Clementia Pharmaceuticals Inc.
- Links
- Website for the International FOP Association
- ID
- NCT03312634
- Phase
- Phase 3 Fibrodysplasia Ossificans Progressiva Research Study
- Study Type
- Interventional
- Participants
- Expecting 110 study participants
- Last Updated